About Verastem (NASDAQ:VSTM)
Verastem, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company's advanced product candidates are VS 6063, VS 4718 and VS 5584. The Company's programs target the Focal Adhesion Kinase (FAK) and the PI3K/mTOR signaling pathways. FAK is a non-receptor tyrosine kinase encoded by the PTK-2 gene that is involved in cellular adhesion and, in cancer, metastatic capability. The Company's VS-6063 (defactinib) and VS 4718 are orally available small molecule compounds designed to inhibit FAK signaling. The Company's VS-5584 is an orally available small molecule that inhibits both mTORC1/2 and PI3K signaling. The Company is engaged in running clinical trials in cancers where there are limited treatment options, including lung, ovarian, lymphoma, pancreatic and other advanced cancers.
Industry, Sector and Symbol
Trailing P/E Ratio-1.77714285714286
Forward P/E Ratio-2.14
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Book Value$1.19 per share
Price / Book2.61
Return on Equity-130.79%
Return on Assets-93.20%
Verastem (NASDAQ:VSTM) Frequently Asked Questions
What is Verastem's stock symbol?
Verastem trades on the NASDAQ under the ticker symbol "VSTM."
How were Verastem's earnings last quarter?
Verastem Inc (NASDAQ:VSTM) posted its earnings results on Tuesday, March, 13th. The biopharmaceutical company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.42) by $0.01. View Verastem's Earnings History.
When will Verastem make its next earnings announcement?
Where is Verastem's stock going? Where will Verastem's stock price be in 2018?
9 brokerages have issued twelve-month price targets for Verastem's stock. Their predictions range from $1.50 to $17.00. On average, they anticipate Verastem's share price to reach $10.94 in the next year. View Analyst Ratings for Verastem.
What are Wall Street analysts saying about Verastem stock?
Here are some recent quotes from research analysts about Verastem stock:
- 1. According to Zacks Investment Research, "Verastem, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing drugs to improve outcomes for patients with cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. Its lead FAK inhibitor is defactinib (VS-6063), an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds. The company's defactinib is in Phase 1b study for the treatment of pancreatic cancer, as well as in Phase 1/2 clinical trial for the treatment of ovarian cancer, non-small cell lung cancer, mesothelioma, and pancreatic cancer. It also engages in developing duvelisib, an investigational oral therapy that targets the PI3K signaling pathway, as well as attacks malignant B-cells and T-cells and disrupt the tumor microenvironment to help thwart their growth and proliferation for patients with lymphatic cancers through the dual inhibition of PI3K delta and gamma. " (3/20/2018)
- 2. Cantor Fitzgerald analysts commented, "Working off Overhangs. We think VSTM shares are undervalued relative to the duvelisib opportunity, and this is partly a function, in our view, of overhangs, particularly cash. VSTM had just under $87 mln in cash, which is sufficient to fund the company into 2H18, but will need additional capital to see duvelisib through commercialization. VSTM has an additional $35 mln available under a debt facility, and the company could add additional cash through a partner deal. It has been our anticipation that VSTM will need to address the capital markets in some way in 2018." (3/13/2018)
- 3. Cann analysts commented, "Verastem announced today that a poster highlighting the synergistic effects of Duvelisib in combination with immune checkpoint or co-stimulatory antibodies in preclinical models of B cell lymphoma was presented at ASCO-SITC Clinical Immuno- Oncology Symposium. The purpose of this study was to evaluate whether Duvelisib therapy could augment the efficacy of immune checkpoint inhibitors or co-stimulatory agents in the A20 mouse model of B cell lymphoma. Verastem reported that as a result of beneficial changes within the tumor microenvironment, it observed enhancement by Duvelisib of the anti-tumor efficacy of immune checkpoint or co-stimulatory antibodies in this preclinical B cell lymphoma model." (1/26/2018)
Who are some of Verastem's key competitors?
Some companies that are related to Verastem include AVEO Pharmaceuticals (AVEO), NicOx (NICXF), Solid Biosciences (SLDB), Nantkwest (NK), Viralytics (VRACY), MannKind (MNKD), Savara (SVRA), Enzo Biochem (ENZ), Catalyst Biosciences (CBIO), Zymeworks (ZYME), BioSpecifics Technologies (BSTC), Osiris Therapeutics (OSIR), DURECT (DRRX), Arbutus Biopharma (ABUS), Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL), Chromadex (CDXC), Catalyst Pharmaceuticals (CPRX) and Viking Therapeutics (VKTX).
Who are Verastem's key executives?
Verastem's management team includes the folowing people:
- Robert Forrester, President, Chief Executive Officer (Age 52)
- Julie B. Feder, Chief Financial Officer (Age 47)
- Daniel W. Paterson, Chief Operating Officer (Age 53)
- Joseph M. Lobacki, Executive Vice President and Chief Commercial Officer (Age 58)
- Joseph Chiapponi, Vice President - Finance (Age 48)
- Monica Kleinman, Vice President, General Counsel (Age 34)
- Michael Ferraresso, Vice President - Commercial Operations
- Lori A. Kunkel M.D., Clinical and Scientific Advisory Board (Age 59)
- Hagop Youssoufian M.D., Head - Hematology and Oncology Development (Age 59)
- Michael G. Kauffman M.D. Ph.D., Lead Independent Director (Age 53)
Has Verastem been receiving favorable news coverage?
Media stories about VSTM stock have been trending somewhat positive this week, Accern reports. Accern scores the sentiment of media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Verastem earned a news impact score of 0.19 on Accern's scale. They also gave media headlines about the biopharmaceutical company an impact score of 46.87 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term.
Who are Verastem's major shareholders?
Verastem's stock is owned by a number of of retail and institutional investors. Top institutional investors include BVF Inc. IL (4.65%), Renaissance Technologies LLC (3.50%), Artal Group S.A. (2.07%), AWM Investment Company Inc. (0.95%), Millennium Management LLC (0.74%) and Monashee Investment Management LLC (0.57%). Company insiders that own Verastem stock include Michael Kauffman and Timothy J Barberich. View Institutional Ownership Trends for Verastem.
Which major investors are selling Verastem stock?
VSTM stock was sold by a variety of institutional investors in the last quarter, including Bogle Investment Management L P DE, Renaissance Technologies LLC, Deutsche Bank AG and Howland Capital Management LLC. View Insider Buying and Selling for Verastem.
Which major investors are buying Verastem stock?
VSTM stock was bought by a variety of institutional investors in the last quarter, including BVF Inc. IL, AWM Investment Company Inc., Monashee Investment Management LLC, Artal Group S.A., Stonepine Capital Management LLC, Alambic Investment Management L.P., Millennium Management LLC and Two Sigma Investments LP. View Insider Buying and Selling for Verastem.
How do I buy shares of Verastem?
Shares of VSTM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Verastem's stock price today?
One share of VSTM stock can currently be purchased for approximately $3.11.
How big of a company is Verastem?
Verastem has a market capitalization of $165.10 million. The biopharmaceutical company earns $-67,800,000.00 in net income (profit) each year or ($1.75) on an earnings per share basis. Verastem employs 69 workers across the globe.
How can I contact Verastem?
Verastem's mailing address is 117 KENDRICK STREET SUITE 500, NEEDHAM MA, 02494. The biopharmaceutical company can be reached via phone at 781-292-4200 or via email at [email protected]
MarketBeat Community Rating for Verastem (VSTM)MarketBeat's community ratings are surveys of what our community members think about Verastem and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Verastem (NASDAQ:VSTM) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Buy|
|Consensus Rating Score: ||2.89||2.88||2.88||2.83|
|Ratings Breakdown: ||0 Sell Rating(s)|
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$10.94||$10.36||$10.64||$5.25|
|Price Target Upside: ||251.69% upside||194.24% upside||248.95% upside||6.71% upside|
Verastem (NASDAQ:VSTM) Consensus Price Target History
Verastem (NASDAQ:VSTM) Analyst Ratings History
(Data available from 3/21/2016 forward)
Verastem (NASDAQ:VSTM) Earnings History and Estimates Chart
Verastem (NASDAQ VSTM) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Verastem (NASDAQ:VSTM) Earnings Estimates
2018 EPS Consensus Estimate: ($1.56)
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Verastem (NASDAQ:VSTM)
No dividend announcements for this company have been tracked by MarketBeat.com
Verastem (NASDAQ VSTM) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 6.51%
Institutional Ownership Percentage: 31.63%
Verastem (NASDAQ VSTM) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|12/5/2017||Timothy J Barberich||Director||Buy||60,538||$3.95||$239,125.10||130,000|| |
|5/15/2017||Timothy J Barberich||Director||Buy||30,000||$2.45||$73,500.00||69,462|| |
|6/29/2015||Monica Singh||General Counsel||Buy||1,000||$6.95||$6,950.00|| |
|6/29/2015||Robert Forrester||CEO||Buy||2,000||$7.11||$14,220.00|| |
|6/18/2015||Dan Paterson||COO||Buy||1,000||$8.05||$8,050.00|| |
|6/17/2015||Robert Forrester||CEO||Buy||1,000||$7.97||$7,970.00|| |
|1/28/2015||Christoph H Westphal||Chairman||Buy||1,230,769||$6.50||$7,999,998.50|| |
|1/28/2015||Timothy J Barberich||Director||Buy||38,462||$6.50||$250,003.00|| |
|12/29/2014||Joanna Horobin||Insider||Buy||750||$8.60||$6,450.00|| |
|12/29/2014||S. Louise Phanstiel||Director||Buy||10,000||$8.54||$85,400.00|| |
|12/26/2014||Stephen A Sherwin||Director||Buy||2,500||$8.56||$21,400.00|| |
|12/24/2014||Paul A Friedman||Director||Buy||3,000||$8.31||$24,930.00|| |
|12/23/2014||Henri A Termeer||Director||Buy||19,100||$8.09||$154,519.00|| |
|12/23/2014||Monica Singh||General Counsel||Buy||1,000||$8.09||$8,090.00|| |
|12/19/2014||Christoph H Westphal||Chairman||Buy||1,500||$8.50||$12,750.00|| |
|12/19/2014||Dan Paterson||COO||Buy||2,000||$8.52||$17,040.00|| |
|12/19/2014||Robert Forrester||CEO||Buy||1,000||$8.66||$8,660.00|| |
|11/11/2014||Alison Frances Lawton||Director||Buy||2,500||$9.17||$22,925.00|| |
|9/17/2014||Michael Kauffman||Director||Buy||3,000||$9.10||$27,300.00|| |
|5/30/2014||Timothy J Barberich||Director||Buy||1,000||$9.90||$9,900.00|| |
|5/20/2014||Richard Aldrich||Director||Buy||1,000||$8.37||$8,370.00||408,142|| |
|5/15/2014||Dan Paterson||Insider||Buy||1,000||$7.47||$7,470.00||58,143|| |
|5/14/2014||Christoph Westphal||Chairman||Buy||2,000||$7.56||$15,120.00||700,264|| |
|5/13/2014||Robert Forrester||CEO||Buy||1,000||$7.62||$7,620.00||239,320|| |
|11/18/2013||Christoph Westphal||Director||Buy||1,000||$9.60||$9,600.00||696,872|| |
|11/11/2013||Richard Aldrich||Director||Buy||1,000||$10.93||$10,930.00||407,142|| |
|11/4/2013||Richard Aldrich||Director||Buy||1,000||$10.51||$10,510.00|| |
|10/28/2013||Richard Aldrich||Director||Buy||1,000||$11.26||$11,260.00|| |
|10/21/2013||Richard Aldrich||Director||Buy||1,000||$12.57||$12,570.00|| |
|10/14/2013||Richard Aldrich||Director||Buy||1,000||$10.56||$10,560.00||407,142|| |
|10/7/2013||Richard Aldrich||Director||Buy||1,000||$11.53||$11,530.00||407,142|| |
|9/30/2013||Richard Aldrich||Director||Buy||1,000||$12.55||$12,550.00||407,142|| |
|9/23/2013||Richard Aldrich||Director||Buy||1,000||$13.17||$13,170.00||407,142|| |
|9/16/2013||Richard Aldrich||Director||Buy||1,000||$13.81||$13,810.00||407,142|| |
|9/9/2013||Richard Aldrich||Director||Buy||1,000||$14.04||$14,040.00|| |
|9/3/2013||Richard Aldrich||Director||Buy||1,000||$14.07||$14,070.00||407,142|| |
|8/26/2013||Richard Aldrich||Director||Buy||1,000||$14.21||$14,210.00||407,142|| |
|8/19/2013||Richard Aldrich||Director||Buy||1,000||$13.45||$13,450.00||407,142|| |
|8/12/2013||Richard Aldrich||Director||Buy||1,000||$14.75||$14,750.00||407,142|| |
|8/5/2013||Richard Aldrich||Director||Buy||1,000||$15.25||$15,250.00||407,142|| |
|7/29/2013||Richard Aldrich||Director||Buy||1,000||$15.15||$15,150.00|| |
|7/24/2013||Richard Aldrich||Director||Buy||1,000||$16.39||$16,390.00|| |
|7/15/2013||Richard Aldrich||Director||Buy||1,000||$17.19||$17,190.00|| |
|7/8/2013||Richard Aldrich||Director||Buy||1,000||$14.69||$14,690.00|| |
|7/1/2013||Richard Aldrich||Director||Buy||1,000||$14.11||$14,110.00|| |
|6/13/2013||Robert Forrester||COO||Buy||1,000||$11.39||$11,390.00|| |
|6/12/2013||Henri A Termeer||Director||Buy||5,823||$9.74||$56,716.02|| |
|6/12/2013||Lp Chp III||Major Shareholder||Buy||48,171||$9.40||$452,807.40|| |
|6/11/2013||S. Louise Phanstiel||Director||Buy||12,000||$9.30||$111,600.00|| |
|6/7/2013||Christoph H Westphal||CEO||Buy||1,000||$9.06||$9,060.00|| |
|5/13/2013||John K Clarke||Director||Buy||25,000||$9.74||$243,500.00|| |
|5/1/2013||John K Clarke||Director||Buy||10,000||$9.66||$96,600.00|| |
|4/17/2013||John K Clarke||Director||Buy||5,631||$9.50||$53,494.50|| |
|12/18/2012||Lp Chp III||Major Shareholder||Buy||6,193||$7.87||$48,738.91|| |
Verastem (NASDAQ VSTM) News Headlines
Verastem (NASDAQ:VSTM) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Verastem (NASDAQ:VSTM) Income Statement, Balance Sheet and Cash Flow Statement
Verastem (NASDAQ VSTM) Stock Chart for Wednesday, March, 21, 2018